The Role of TGF-β in Bone Metastases
Open Access
- 6 November 2021
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 11 (11) , 1643
Abstract
Complications associated with advanced cancer are a major clinical challenge and, if associated with bone metastases, worsen the prognosis and compromise the survival of the patients. Breast and prostate cancer cells exhibit a high propensity to metastasize to bone. The bone microenvironment is unique, providing fertile soil for cancer cell propagation, while mineralized bone matrices store potent growth factors and cytokines. Biologically active transforming growth factor β (TGF-β), one of the most abundant growth factors, is released following tumor-induced osteoclastic bone resorption. TGF-β promotes tumor cell secretion of factors that accelerate bone loss and fuel tumor cells to colonize. Thus, TGF-β is critical for driving the feed-forward vicious cycle of tumor growth in bone. Further, TGF-β promotes epithelial-mesenchymal transition (EMT), increasing cell invasiveness, angiogenesis, and metastatic progression. Emerging evidence shows TGF-β suppresses immune responses, enabling opportunistic cancer cells to escape immune checkpoints and promote bone metastases. Blocking TGF-β signaling pathways could disrupt the vicious cycle, revert EMT, and enhance immune response. However, TGF-β’s dual role as both tumor suppressor and enhancer presents a significant challenge in developing therapeutics that target TGF-β signaling. This review presents TGF-β’s role in cancer progression and bone metastases, while highlighting current perspectives on the therapeutic potential of targeting TGF-β pathways.Keywords
This publication has 200 references indexed in Scilit:
- Expression of GATA3 in MDA-MB-231 Triple-negative Breast Cancer Cells Induces a Growth Inhibitory Response to TGFßPLOS ONE, 2013
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunityCurrent Opinion in Immunology, 2012
- Blockade of transforming growth factor‐beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell lineThe Prostate, 2011
- Cellular mechanisms of bone remodelingReviews in Endocrine and Metabolic Disorders, 2010
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TANCancer Cell, 2009
- Non-Smad pathways in TGF-β signalingCell Research, 2008
- An Id‐like molecule, HHM, is a synexpression group‐restricted regulator of TGF‐β signallingThe EMBO Journal, 2008
- TRAF6 Mediates Smad-Independent Activation of JNK and p38 by TGF-βMolecular Cell, 2008
- TGFβ in CancerCell, 2008
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003